Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EBIT (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed EBIT for 5 consecutive years, with -$6.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 49.87% to -$6.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$35.3 million, a 65.18% increase, with the full-year FY2024 number at -$96.3 million, down 43.55% from a year prior.
  • EBIT was -$6.2 million for Q3 2025 at Lyra Therapeutics, up from -$8.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$6.2 million in Q3 2025 to a low of -$49.0 million in Q2 2024.
  • A 5-year average of -$15.1 million and a median of -$13.6 million in 2021 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 196.76% in 2024, then surged 81.98% in 2025.
  • Lyra Therapeutics' EBIT stood at -$13.6 million in 2021, then fell by 11.12% to -$15.2 million in 2022, then dropped by 8.72% to -$16.5 million in 2023, then surged by 30.76% to -$11.4 million in 2024, then surged by 45.33% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EBIT are -$6.2 million (Q3 2025), -$8.8 million (Q2 2025), and -$8.8 million (Q1 2025).